These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21697649)

  • 1. Assessment of biochemical control of acromegaly during treatment with somatostatin analogues by oral glucose load and insulin-like growth factor I.
    Scacchi M; Carzaniga C; Vitale G; Fatti LM; Pecori Giraldi F; Andrioli M; Cattaneo A; Cavagnini F
    J Endocrinol Invest; 2011 Oct; 34(9):e291-5. PubMed ID: 21697649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatment.
    Reimondo G; Bondanelli M; Ambrosio MR; Grimaldi F; Zaggia B; Zatelli MC; Allasino B; Laino F; Aroasio E; Termine A; Conton P; Paoletta A; Demenis E; Uberti ED; Terzolo M
    Endocrine; 2014 Feb; 45(1):122-7. PubMed ID: 23794116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
    Carmichael JD; Bonert VS; Mirocha JM; Melmed S
    J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
    Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study.
    Petersenn S; Houchard A; Sert C; Caron PJ;
    Pituitary; 2020 Apr; 23(2):171-181. PubMed ID: 31879842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
    Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly.
    Sherlock M; Aragon Alonso A; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):74-81. PubMed ID: 19178529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acromegaly.
    Scacchi M; Cavagnini F
    Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment.
    Baldelli R; Battista C; Leonetti F; Ghiggi MR; Ribaudo MC; Paoloni A; D'Amico E; Ferretti E; Baratta R; Liuzzi A; Trischitta V; Tamburrano G
    Clin Endocrinol (Oxf); 2003 Oct; 59(4):492-9. PubMed ID: 14510913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender and age in the biochemical assessment of cure of acromegaly.
    Freda PU; Landman RE; Sundeen RE; Post KD
    Pituitary; 2001 Aug; 4(3):163-71. PubMed ID: 12138989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide.
    Díez JJ; Iglesias P; Gómez-Pan A
    J Endocrinol Invest; 2001 May; 24(5):303-9. PubMed ID: 11407648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
    Cozzi R; Attanasio R; Lodrini S; Lasio G
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?
    Cozzi R; Attanasio R; Grottoli S; Pagani G; Loli P; Gasco V; Pedroncelli AM; Montini M; Ghigo E
    J Endocrinol Invest; 2004 Dec; 27(11):1040-7. PubMed ID: 15754736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycemic profile in patients with acromegaly treated with somatostatin analogue.
    Valea A; Carsote M; Ghervan C; Georgescu C
    J Med Life; 2015; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery.
    Rubeck KZ; Madsen M; Andreasen CM; Fisker S; Frystyk J; Jørgensen JO
    Eur J Endocrinol; 2010 Nov; 163(5):717-26. PubMed ID: 20813787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
    Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
    Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
    Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide.
    Attanasio R; Barausse M; Cozzi R
    J Endocrinol Invest; 2001 Apr; 24(4):209-16. PubMed ID: 11383906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.